Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives

References

• Kelly E, Russell SJ. History of oncolytic viruse: genesis to genetic engineering. Mol Ther. 2007;15:651–659.
   PubMed Web of Science ®Google Scholar
• Levaditi C, Nicolau S. Sur la culture du virus vaccinale dans les néoplasmesépithéliaux. CR Soc Biol. 1922;86:928.
   Google Scholar
• Dock G. The influence of complicating diseases upon leukemia. Am J Med Sci. 1904;127:563–582.
   Google Scholar
• Pace NG. Sulla scomparsa di un enorme cancro vegetante del collo dell’utero senza cura chirurgica. Ginecologia. 1912;9:82–88.
   Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788.
   PubMed Web of Science ®Google Scholar
• Kyula JN, Roulstone V, Karapanagiotou EM, et al. Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther. 2012;12:1669–1678.
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–336.
   PubMed Web of Science ®Google Scholar
• Nüesch JP, Lacroix J, Marchini A, et al. Molecular pathways: rodent parvoviruses–mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res. 2012;18:3516–3523.
   PubMed Web of Science ®Google Scholar
• Ozawa K, Ayub J, Kajigaya S, et al. The gene encoding the non-structural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol. 1988;62:2884–2889.
   PubMed Web of Science ®Google Scholar
• Sol N, Junter JL, Vassias I, et al. Possible interaction between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol. 1999;73:8762–8770.
   PubMed Web of Science ®Google Scholar
• Morey AL, Ferguson DJP, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus-B19 in vitro evidence of cell-death by apoptosis. J Pathol. 1993;169:213–220.
   PubMed Web of Science ®Google Scholar
• Baker DG. Natural pathogens of laboratory mice, rats and rabbits and their effects on research. Microbiol Rev. 1998;11:231–266.
   Google Scholar
• Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods. 1991;33:233–251.
   PubMed Web of Science ®Google Scholar
• Nüesch JPF. Regulation of non-structural protein functions by differential synthesis, modification and trafficking. In: Kerr JR, Cotmore SF, Bloom ME, et al., editors. Parvoviruses. London: Hodder Arnold; 2006. p. 275–287.
   Google Scholar
• Li J, Bonifati S, Hristov G, et al. Synergistic combination of valproic acid and oncolytic parvovirus H1-PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med. 2013;5:1537–1555.
   PubMed Web of Science ®Google Scholar
• Cornelis JJ, Deleu L, Koch U, et al. Parvovirus oncosuppression. In: Kerr JR, Cotmore SF, Bloom ME, et al., editors. Parvoviruses. London: Hodder Arnold; 2006. p. 365–384.
   Google Scholar
• Marchiani A, Bonifati S, Scott EM, et al. Oncolytic parvoviruses: from basic virology to clinical applications. Virol J. 2015;12:6.
   PubMed Web of Science ®Google Scholar
• Angelova AL, Geletneky K, Nüesch JP, et al. Tumor selectivity of oncolytic parvoviruses: from in vitro and animal models to cancer patients. Front Bioeng Biotechnol. 2015;3:55.
   PubMed Web of Science ®Google Scholar
• Raykov Z, Grekova G, Galabov AS, et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep. 2007;17:1493–1499.
   PubMed Web of Science ®Google Scholar
• Grekova S, Aprahamian M, Giese N, et al. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol Ther. 2010;10:1280–1289.
   PubMed Web of Science ®Google Scholar
• Angelova AL, Grekova SP, Heller A, et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol. 2014;88:5263–5276.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Harrington KJ, Pandha HS, et al. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008;8:1581–1588.
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Foreyth PAJ, et al. Recent progress in the battle between oncolytic viruses and tumors. Nat Rev Cancer. 2005;5:965–976.
   PubMed Web of Science ®Google Scholar
• Wollmann G, Odzuman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 2012;18:69–81.
   PubMed Web of Science ®Google Scholar
• Mullen JT, Tanabe KK. Viral oncolysis. Oncologist. 2002;7:103–119.
   PubMed Web of Science ®Google Scholar
• Alvarez-Breckenridge CA, Yu J, Kaur B, et al. Deciphering the multifaceted relationship between oncolytic viruses and natural killer cells. Adv Virol. 2012. doi:10.1155/2012/702839.
   PubMedGoogle Scholar
• [ cited 2016 Jan]. Available from: https://clinicaltrials.gov/ct2/results?term=viral+therapy
   Google Scholar
• Dupressoir T, Vanacker JM, Cornelis JJ, et al. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. 1989;49:3203–3208.
   PubMed Web of Science ®Google Scholar
• Herrero YCM, Cornelis JJ, Herold-Mende C, et al. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004;109:78–84.
   Google Scholar
• Geletneky K, Hartkopf AD, Krempien R, et al. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection. J Biomed Biotechnol. 2010;2010:350748.
   PubMedGoogle Scholar
• Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study of intratumoral/ intracerebral or intravenous/intracerebral administration of Parvovirus H-1(ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 2012;12:99.
   PubMed Web of Science ®Google Scholar
• Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11:375–383.
   PubMed Web of Science ®Google Scholar
• Angelova AL, Aprahamian M, Balboni G, et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther. 2009;17:1164–1172.
   PubMed Web of Science ®Google Scholar
• Moehler MH, Zeidler M, Wilsberg V, et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther. 2005;16:996–1005.
   PubMed Web of Science ®Google Scholar
• Stomach cancer. Estimated incidence, mortality and prevalence in 2012. [ cited 2016 Jan]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp
   Google Scholar
• Liu J, Ran ZH, Xiao SD, et al. Changes in gene expression profiles induced by parvovirus H-1 in human gastric cancer cells. Chin J Dig Dis. 2005;6:72–81.
   PubMedGoogle Scholar
• Zhao D, Cai C, Wang Y, et al. Specific anti-gastric cancer effects of a recombinant plasmid expressing non-structural protein 1 of parvovirus H1. Saudi Med J. 2014;35:336–345.
   PubMed Web of Science ®Google Scholar
• Wang YY, Liu J, Zheng Q, et al. Effect of the parvovirus H-1 non-structural protein NS1 on the tumorigenicity of human gastric cancer cells. J Dig Dis. 2012;13:366–373.
   PubMed Web of Science ®Google Scholar
• Liver cancer. Estimated incidence, mortality and prevalence in 2012. [ cited 2016 Jan]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp
   Google Scholar
• Moehler M, Blechacz B, Weiskopf N, et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther. 2001;8:158–167.
   PubMed Web of Science ®Google Scholar
• Raykov Z, Balboni G, Aprahamian M, et al. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer. 2004;109:742–749.
   PubMed Web of Science ®Google Scholar
• Colorectal cancer. Estimated incidence, mortality and prevalence in 2012. [ cited 2016 Jan]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp
   Google Scholar
• Malerba M, Daeffler L, Rommelaere J, et al. Replicating parvoviruses that target colon cancer cells. J Virol. 2003;77:6683–6691.
   PubMed Web of Science ®Google Scholar
• Malerba M, Nikolova D, Cornelis J, et al. Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter. Cancer Gene Ther. 2006;13:273–280.
   PubMed Web of Science ®Google Scholar
• Heinrich B, Goepfert K, Delic M, et al. Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. Onco Targets Ther. 2013;6:1119–1127.
   PubMed Web of Science ®Google Scholar
• Bhat R, Rommelaere J. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer. 2013;13:367.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Raykov Z, Georgieva PB, Angelova A, et al. Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines. ActaVirol. 2009;53:57–60.
   Google Scholar
• Kaowinn S, Cho IR, Moon J, et al. Pancreatic adenocarcinoma upregulated factor (PAUF) confers resistance to pancreatic cancer cells against oncolytic parvovirus H-1 infection through IFNA receptor-mediated signaling. Biochem Biophys Res Commun. 2015;459:313–318.
   PubMed Web of Science ®Google Scholar
• Dempe S, Stroh-Dege AY, Schwarz E, et al. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV. Int J Cancer. 2010;126:2914–2927.
   PubMed Web of Science ®Google Scholar
• Bhat R, Dempe S, Dinsart C, et al. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer. 2011;128:908–919.
   PubMed Web of Science ®Google Scholar
• Angelova AL, Aprahamian M, Grekova SP, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009;15:511–519.
   PubMed Web of Science ®Google Scholar
• Grekova SP, Aprahamian M, Daeffler L, et al. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol Ther. 2011;12:888–895.
   PubMed Web of Science ®Google Scholar
• Dempe S, Lavie M, Struyf S, et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother. 2012;61:2113–2123.
   PubMed Web of Science ®Google Scholar
• Réjiba S, Bigand C, Parmentier C, et al. Oncosuppressive suicide gene virotherapy “PVH1-yCD/5-FC” for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement. PLoS One. 2013;8:e70594.
   PubMed Web of Science ®Google Scholar
• Angelova AL, Grekova SP, Heller A, et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol. 2014;88:5263–5276.
   PubMed Web of Science ®Google Scholar
• Grekova SP, Aprahamian M, Giese NA, et al. Genomic CpG enrichment of oncolytic parvovirusrs as a potent anticancer vaccination strategy for the treatment of pancreatic adenocarcinoma. J Vaccines Vaccin. 2014;5:2.
   Google Scholar
• Raykov Z, Grekova SP, Hörlein R, et al. TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells. PLoS One. 2013;8:e55086.
   PubMed Web of Science ®Google Scholar
• Geletneky K, Leoni AL, Pohlmeyer-Esch G, et al. Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. Comp Med. 2015;65:36–45.
   PubMed Web of Science ®Google Scholar
• Enderlin M, Kleinmann EV, Struyf S, et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther. 2009;16:149–160.
   PubMed Web of Science ®Google Scholar
• Haag A, Menten P, Van Damme J, et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther. 2000;11:597–609.
   PubMed Web of Science ®Google Scholar
• Giese NA, Raykov Z, DeMartino L, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 2002;9:432–442.
   PubMed Web of Science ®Google Scholar
• Wetzel K, Struyf S, Van Damme J, et al. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer. 2007;120:1364–1371.
   PubMed Web of Science ®Google Scholar
• Lavie M, Struyf S, Stroh-Dege A, et al. Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis. Virology. 2013;447:221–232.
   PubMed Web of Science ®Google Scholar
• Raykov Z, Grekova S, Leuchs B, et al. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer. 2008;122:2880–2884.
   PubMed Web of Science ®Google Scholar